Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
Limit of detection of 0.02% or better enables accurate molecular profiling for treatment selection and dynamic monitoring of response to therapy using a simple blood sample     SAN DIEGO , Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML
Toggle Summary Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 37 issued patents globally for highly sensitive methods of detecting cancer biomarkers     SAN DIEGO , Oct. 3, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
View HTML
Toggle Summary Biocept to Present at Two Investment Conferences in September
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at
View HTML
Toggle Summary High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01% SAN DIEGO , Aug. 22, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells
New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients with cancer Biocept now has 36 issued patents globally covering its novel liquid biopsy
View HTML
Toggle Summary Biocept Reports Second Quarter 2019 Financial Results
- Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 - Revenues for the first six-month of 2019 increased 36% and commercial samples increased 18% over the first six months of 2018 - Conference call begins at 4:30 p.m.
View HTML
Toggle Summary Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®
BeaconLBS now offers Biocept's Target Selector™ testing for liquid biopsy as part of its laboratory management network in the United States SAN DIEGO , July 22, 2019 /PRNewswire/ --  Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians
View HTML
Toggle Summary Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , June 18, 2019 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4
SAN DIEGO , June 3, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML